Skip to content
Screener

Interest Income at other companies

Incyte logo
IncyteINCY
$38.12M+51.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$3.65M-38.4%
TTR
Turn Therapeutics Inc.TTRX
$49.68K+862%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestAndOtherIncome.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
General and administrative13,10310,39124,55221,211
Total operating expenses80,64564,587165,095128,021
Operating loss(80,623)(63,857)(165,058)(126,597)
Investment and other income, net7,1207,25712,87016,201
Net loss$(73,503)$(56,600)$(152,188)$(110,396)
Basic and diluted net loss per common share$(0.94)$(0.85)$(2.11)$(1.66)
Shares used in calculating basic and diluted net loss per share77,84066,39272,23466,388
Comprehensive loss:

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's interest income?
Celldex Therapeutics (CLDX) reported interest income of $7.12M in Q2 2026.
How has Celldex Therapeutics's interest income changed year-over-year?
Celldex Therapeutics's interest income decreased by 1.9% year-over-year, from $7.26M to $7.12M.
What is the long-term trend for Celldex Therapeutics's interest income?
Over 4 years (2021 to 2025), Celldex Therapeutics's interest income has grown at a 174.3% compound annual growth rate (CAGR), from $505K to $28.61M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Celldex Therapeutics's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude